New 3-Year Extension Study Results Observed for Deucravacitinib Treatment of Plaque Psoriasis
The new data on this drug’s effects on maintenance of clinical response indicates the strength of the treatment for individuals with the immune-mediated skin disease.
Source: hcplive.com